Eli Lilly and Company (LLY)
NYSE · Indianapolis, Indiana, USA · Founded 1876 · CEO David Ricks
Valuation summary
$1,268.82 fair value versus $1,351.12 in the market, a difference of -6.1%. Rated Hold.
| Fair value per share | $1,268.82 |
| Current share price | $1,351.12 |
| Upside / downside | -6.1% |
| Bear case | $854.04 |
| Bull case | $1,854.23 |
| Discount rate (WACC) | 8.6% |
| Terminal growth | 3.00% |
| Market capitalisation | $1,271B |
| EV / Sales | 14.4x |
About Eli Lilly and Company
Founded in 1876 by Colonel Eli Lilly, a Union Army veteran and pharmaceutical chemist, in Indianapolis, where it is still headquartered. David Ricks has been CEO since 2017. Lilly was the first company to mass-produce insulin and later the polio vaccine. Today it is defined by the incretin franchise: Mounjaro for type 2 diabetes and Zepbound for obesity, both tirzepatide. Its oral GLP-1 pill, Foundayo, received FDA approval on 1 April 2026, opening the market to patients unwilling to inject. Other products include Verzenio in oncology and donanemab for Alzheimer's.
Investment case
- The obesity market is one of the largest addressable opportunities in pharmaceutical history and Lilly has the best-in-class molecule.
- Oral GLP-1 approval in April 2026 removes the injection barrier and expands the treatable population enormously.
- Manufacturing capacity investment has been aggressive and early, which has been the binding constraint for the whole category.
Key risks
- Payer pushback on pricing is intensifying as obesity drug spending becomes a visible line item in health budgets.
- Compounded and counterfeit GLP-1 supply undercuts pricing in the cash-pay segment.
- Patent expiry on tirzepatide arrives in the 2030s and the next franchise has to be built before then.
Recent developments
- 2026-10-29 · Q3 revenue up 39% to $24.4bn as Mounjaro reaches $10.7bn and Zepbound $5.4bn; 2026 revenue guide raised to $91bn-$92bn source
- 2026-09-29 · Phase 3 TRIUMPH-2: retatrutide produced up to 20.8% weight loss at 80 weeks in type 2 diabetes; US filing planned Q1 2027 source
- 2026-09-11 · Lilly completed its acquisition of AtaiBeckley, adding rapid-acting treatments for treatment-resistant depression source
- 2026-08-31 · Lilly agreed to acquire Merida Biosciences for up to $2.875bn in cash, including milestones source
Revenue by segment
| Diabetes & Obesity (incretins) | 62% |
| Oncology | 16% |
| Immunology | 10% |
| Neuroscience & Other | 12% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $132.0B | $36.0B |
| Year 2 | $179.6B | $47.6B |
| Year 3 | $228.5B | $58.8B |
| Year 4 | $270.3B | $67.4B |
| Year 5 | $295.6B | $71.5B |
What the street says
One of the most consistently favoured large-cap pharma names, with the debate focused on pricing durability rather than demand. Third-quarter 2026 revenue rose 39% to $24.4bn on Mounjaro ($10.7bn) and Zepbound ($5.4bn), and the 2026 revenue guide was raised to $91-92bn, although the EPS range was trimmed for acquired research charges. Phase 3 retatrutide data showing up to 20.8% weight loss in people with type 2 diabetes support a planned US filing in Q1 2027.
Comparable companies: ARGX · ABBV · JNJ · AMGN · GILD · VRTX · ALNY · NVO
Open the interactive model, price chart and sensitivity grid →